RxDoctor Payments Data

Richard Flowers, MD

Infectious Disease · Jackson, MSNPI 1356364905

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Smith+Nephew at 28.2% of the total. Reporting peaked in 2019 at $503 and has fallen 91.4% since, to $43 in 2025.

$1,321in general payments, 2019–2025

Across 62 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$372
  • AbbVie$291
  • Melinta Therapeutics, LLC$162
  • Medline Industries LP$67
  • Convatec Inc.$67
  • Aroa Biosurgery Incorporated$65
  • plus $298 from 9 others

What the payments were for

  • Food & beverage$1,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,321 in reported general payments places this provider in the 75th percentile of 36 infectious disease providers in Mississippi.

See all infectious disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$57,572
Medicare patients
106
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TeflaroCeftaroline Fosamil Acetate11$29,258
Daptomycin43$23,051
Vancomycin Hcl38$5,204
ErtapenemErtapenem Sodium25$4,882
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam30$4,543
Moxifloxacin Hcl33$2,010
Gentamicin Sulfate23$1,397
Ceftazidime21$1,266
Sodium Chloride0.9 % Sodium Chloride94$1,112
Linezolid16$961
Doxycycline Hyclate20$693
Clindamycin Hcl27$618
Triamcinolone Acetonide33$355
Cefdinir12$253
Levofloxacin41$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieTeflaro$291$29,25811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 36 infectious disease providers in Mississippi.

Other infectious disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →